Application of SELDI-TOF-mass spectrometry for biomarker identification: Potentials and limitations;Anwendung der SELDI-TOF-massenspektrometrie zur identifizierung neuer biomarker: Möglichkeiten und grenzen

LaboratoriumsMedizin

Volumn 31, Issue 3, 2007, Pages 93-108

  Kiehntopf, Michael ^a   Siegmund, Robert ^a   Deufel, Thomas ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Biomarker identification; Mass spectrometry; Protein profiling; Proteomics; SELDI TOF MS

Indexed keywords

BIOLOGICAL MARKER;

ACCURACY; ARTICLE; BIOINFORMATICS; BIOTECHNOLOGY; CONTROL GROUP; DATA ANALYSIS; DIAGNOSTIC VALUE; HIGH THROUGHPUT SCREENING; HUMAN; LABORATORY TEST; MICROARRAY ANALYSIS; NONHUMAN; PILOT STUDY; PROTEIN ANALYSIS; PROTEOMICS; QUALITY CONTROL; REPRODUCIBILITY; STANDARD; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TIME; VALIDATION PROCESS;

EID: 34250718222     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/JLM.2007.021     Document Type: Article

References (131)

1. Weston AD, Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res 2004;3:179-96.
2. Wrotnowski C. The future of plasma proteins. Genet Eng News 1998;18:14.
3. Basso D, Valerio A, Seraglia R, Mazza S, Piva MG, Greco E, et al. Putative pancreatic cancer-associated diabetogenic factor: 2030 MW peptide. Pancreas 2002;24:8-14.
4. Jang JS, Cho HY, Lee YJ, Ha WS, Kim HW. The differential proteome profile of stomach cancer: identification of the biomarker candidates. Oncol Res 2004;14:491-9.
5. Petricoin EE, Paweletz CP, Liotta LA. Clinical applications of proteomics: proteomic pattern diagnostics. J Mammary Gland Biol Neoplasia 2002;7:433-40.
6. Liotta LA, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature 2003;425:905.
7. Anderson NG, Anderson NL. Twenty years of two-dimensional electrophoresis: past, present and future. Electrophoresis 1996;17:443-53.
8. Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004;4:3665-85.
9. Mitulovic G, Stingl C, Smoluch M, Swart R, Chervet JP, Steinmacher I, et al. Automated, on-line two-dimensional nano liquid chromatography tandem mass spectrometry for rapid analysis of complex protein digests. Proteomics 2004;4:2545-57.
10. Lu Y, Bottari P, Turecek F, Aebersold R, Gelb MH. Absolute quantification of specific proteins in complex mixtures using visible isotope-coded affinity tags. Anal Chem 2004;76:4104-11.
11. Moseley MA. Current trends in differential expression proteomics: isotopically coded tags. Trends Biotechnol 2001;19:S10-6.
12. Fujii K, Nakano T, Kawamura T, Usui F, Bando Y, Wang R, et al. Multidimensional protein profiling technology and its application to human plasma proteome. J Proteome Res 2004;3:712-8.
13. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003;2:1096-103.
14. Wang Y, Walles M, Thomson B, Nacson S, Pawliszyn J. Solid-phase microextraction combined with surface-enhanced laser desorption/ionization introduction for ion mobility spectrometry and mass spectrometry using polypyrrole coatings. Rapid Commun Mass Spectrom 2004;18:157-62.
15. Seibert V, Wiesner A, Buschmann T, Meuer J. Surfaceenhanced laser desorption ionization time-of-flight mass spectrometry (SELDI TOF-MS) and ProteinChip technology in proteomics research. Pathol Res Pract 2004;200:83-94.
16. Wright GL Jr. SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis. Expert Rev Mol Diagn 2002;2:549-63.
17. Hutchens TW, Yip TT. New desorption strategies for the mess spectrometric analysis of macromolecules. Rapid Commun Mass Spectrom 1993;7:576-580.
18. Garbis S, Lubec G, Fountoulakis M. Limitations of current proteomics technologies. J Chromatogr A 2005;1077:1-18.
19. Young DS, Tracy RP. Clinical applications of two-dimensional electrophoresis. J Chromatogr A 1995;698:163-79.
20. Paweletz CP, Liotta LA, Petricoin EF 3rd. New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics. Urology 2001;57:160-3.
21. Wiesner A. Detection of tumor markers with ProteinChip technology. Curr Pharm Biotechnol 2004;5:45-67.
22. Diamond DL, Zhang Y, Gaiger A, Smithgall M, Vedvick TS, Carter D. Use of ProteinChip array surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) to identify thymosin beta-4, a differentially secreted protein from lymphoblastoid cell lines. J Am Soc Mass Spectrom 2003;14:760-5.
23. Jorgensen CS, Jagd M, Sorensen BK, McGuire J, Barkholt V, Hojrup P, et al. Efficacy and compatibility with mass spectrometry of methods for elution of proteins from sodium dodecyl sulfate-polyacrylamide gels and polyvinyldifluoride membranes. Anal Biochem 2004;330:87-97.
24. Melle C, Ernst G, Scheibner O, Kaufmann R, Schimmel B, Bleul A, et al. Identification of specific protein markers in microdissected hepatocellular carcinoma. J Proteome Res 2007;6:306-15.
25. Caputo E, Moharram R, Martin BM. Methods for on-chip protein analysis. Anal Biochem 2003;321:116-24.
26. Hinshelwood J, Spencer DI, Edwards YJ, Perkins SJ. Identification of the C3b binding site in a recombinant vWF-A domain of complement factor B by surface-enhanced laser desorption-ionisation affinity mass spectrometry and homology modelling: implications for the activity of factor B. J Mol Biol 1999;294:587-99.
27. Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C, et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 2001;276:16772-9.
28. Bane TK, LeBlanc JF, Lee TD, Riggs AD. DNA affinity capture and protein profiling by SELDI-TOF mass spectrometry: effect of DNA methylation. Nucleic Acids Res 2002;30:e69.
29. Thulasiraman V, Wang Z, Katrekar A, Lomas L, Yip TT. Simultaneous monitoring of multiple kinase activities by SELDI-TOF mass spectrometry. Methods Mol Biol 2004;264:205-14.
30. Coombes KR, Fritsche HA Jr., Clarke C, Chen JN, Baggerly KA, Morris JS, et al. Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. Clin Chem 2003;49:1615-23.
31. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 2002;48:1296-304.
32. Wiesner A. Detection of Tumor Markers with ProteinChip(R) Technology. Curr Pharm Biotechnol 2004;5:45-67.
33. Pang RT, Poon TC, Chan KC, Lee NL, Chiu RW, Tong YK, et al. Serum proteomic fingerprints of adult patients with severe acute respiratory syndrome. Clin Chem 2006;52:421-9.
34. Poon TC, Hui AY, Chan HL, Ang IL, Chow SM, Wong N, et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem 2005;51:328-35.
35. Poon TC, Sung JJ, Chow SM, Ng EK, Yu AC, Chu ES, et al. Diagnosis of gastric cancer by serum proteomic fingerprinting. Gastroenterology 2006;130:1858-64.
36. Fung ET, Enderwick C. ProteinChip clinical proteomics: computational challenges and solutions. Biotechniques 2002;Suppl:34-8, 40-1.
37. Bender R, Lange S. Adjusting for multiple testing - when and how? J Clin Epidemiol 2001;54:343-9.
38. Bender R, Lange S. Was ist der P-Wert? Dtsch med Wschr 2001;126:T39-T40.
39. Poon TC. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev Proteomics 2007;4:51-65.
40. Zhang S. An improved nonparametric approach for detecting differentially expressed genes with replicated microarray data. Stat Appl Genet Mol Biol 2006;5:Article 30.
41. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;98:5116-21.
42. Pan W, Lin J, Le CT. A mixture model approach to detecting differentially expressed genes with microarray data. Funct Integr Genomics 2003;3:117-24.
43. Poon TC, Yip TT, Chan AT, Yip C, Yip V, Mok TS, et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 2003;49:752-60.
44. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
45. Agranoff D, Stich A, Abel P, Krishna S. Proteomic fingerprinting for the diagnosis of human African trypanosomiasis. Trends Parasitol 2005;21:154-7.
46. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-14.
47. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004;4:309-14.
48. Kang X, Xu Y, Wu X, Liang Y, Wang C, Guo J, et al. Proteomic fingerprints for potential application to early diagnosis of severe acute respiratory syndrome. Clin Chem 2005;51:56-64.
49. Kiehntopf M, Osterloh D, Driesch D, Eggeling Fv, Melle C, Brunkhorst FM, et al. Verbesserte Sepsis-Diagnose durch Protein-Chip-Analyse. In: 7.Hj.-Staudinger Symposium der Deutschen Vereinten Gesellschaft für Klinische Chemie und Laboratoriumsmedizin. 27-30.Juli 2004, DGKL 2004; Kloster Banz; 2004.
50. Katz MH. Multivariable analysis: a primer for readers of medical research. Ann Intern Med 2003;138:644-50.
51. Ebert MP, Meuer J, Wiemer JC, Schulz HU, Reymond MA, Traugott U, et al. Identification of gastric cancer patients by serum protein profiling. J Proteome Res 2004;3:1261-6.
52. Karsan A, Eigl BJ, Flibotte S, Gelmon K, Switzer P, Hassell P, et al. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin Chem 2005;51:1525-8.
53. Zhang X, Lu X, Shi Q, Xu XQ, Leung HC, Harris LN, et al. Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. BMC Bioinformatics 2006;7:197.
54. Friedman JH, Hastie T, Tibshirani R. Additive logistic regression: a statistical view of boosting. Ann Stat 2000;28:337-407.
55. Yasui Y, Pepe M, Thompson ML, Adam BL, Wright GL Jr, Qu Y, et al. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. Biostatistics 2003;4:449-63.
56. Forde CE, Gonzales AD, Smessaert JM, Murphy GA, Shields SJ, Fitch JP, et al. A rapid method to capture and screen for transcription factors by SELDI mass spectrometry. Biochem Biophys Res Commun 2002;290:1328-35.
57. Peronnet E, Becquart L, Poirier F, Cubizolles M, Choquet-Kastylevsky G, Jolivet-Reynaud C. SELDI-TOF MS analysis of the Cardiac Troponin I forms present in plasma from patients with myocardial infarction. Proteomics 2006;6:6288-99.
58. Schweigert FJ. Characterisation of protein microheterogeneity and protein complexes using on-chip immunoaffinity purification-mass spectrometry. Brief Funct Genomic Proteomic 2005;4:7-15.
59. Fung ET, Yip TT, Lomas L, Wang Z, Yip C, Meng XY, et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 2005;115:783-9.
60. Melle C, Ernst G, Schimmel B, Bleul A, Koscielny S, Wiesner A, et al. Biomarker discovery and identification in laser microdissected head and neck squamous cell carcinoma with ProteinChip technology, two-dimensional gel electrophoresis, tandem mass spectrometry, and immunohistochemistry. Mol Cell Proteomics 2003;2:443-52.
61. Traub F, Feist H, Kreipe HH, Pich A. SELDI-MS-based expression profiling of ductal invasive and lobular invasive human breast carcinomas. Pathol Res Pract 2005;201:763-70.
62. Engwegen JY, Gast MC, Schellens JH, Beijnen JH. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci 2006;27:251-9.
63. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004;64:5882-90.
64. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004;3:355-66.
65. Zhukov TA, Johanson RA, Cantor AB, Clark RA, Tockman MS. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer 2003;40:267-79.
66. Le L, Chi K, Tyldesley S, Flibotte S, Diamond DL, Kuzyk MA, et al. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem 2005;51:695-707.
67. Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005;51:102-12.
68. Wagner M, Naik DN, Pothen A, Kasukurti S, Devineni RR, Adam BL, et al. Computational protein biomarker prediction: a case study for prostate cancer. BMC Bioinformatics 2004;5:26.
69. Petricoin EF 3rd, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94:1576-8.
70. Martin DB, Gifford DR, Wright ME, Keller A, Yi E, Goodlett DR, et al. Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res 2004;64:347-55.
71. Lehrer S, Roboz J, Ding H, Zhao S, Diamond EJ, Holland JF, et al. Putative protein markers in the sera of men with prostatic neoplasms. BJU Int 2003;92:223-5.
72. Grizzle WE, Semmes OJ, Basler J, Izbicka E, Feng Z, Kagan J, et al. The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genito-urinary oncology. Urol Oncol 2004;22:337-43.
73. Zhang YF, Wu DL, Guan M, Liu WW, Wu Z, Chen YM, et al. Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient. Clin Biochem 2004;37:772-9.
74. Li J, Orlandi R, White CN, Rosenzweig J, Zhao J, Seregni E, et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 2005;51:2229-35.
75. Wulfkuhle JD, McLean KC, Paweletz CP, Sgroi DC, Trock BJ, Steeg PS, et al. New approaches to proteomic analysis of breast cancer. Proteomics 2001;1:1205-15.
76. Vlahou A, Laronga C, Wilson L, Gregory B, Fournier K, McGaughey D, et al. A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer 2003;4:203-9.
77. Paradis V, Degos F, Dargere D, Pham N, Belghiti J, Degott C, et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 2005;41:40-7.
78. Wadsworth JT, Somers KD, Cazares LH, Malik G, Adam BL, Stack BC Jr, et al. Serum protein profiles to identify head and neck cancer. Clin Cancer Res 2004;10:1625-32.
79. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004;20:777-85.
80. Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 2005;97:307-9.
81. Diamandis EP. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003;49:1272-5.
82. Diamandis EP, van der Merwe DE. Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin Cancer Res 2005;11:963-5.
83. Sorace JM, Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 2003;4:24.
84. Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA, et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 2003;100:12343-8.
85. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005;5:4589-96.
86. Mathelin C, Cromer A, Wendling C, Tomasetto C, Rio MC. Serum biomarkers for detection of breast cancers: A prospective study. Breast Cancer Res Treat 2006;96:83-90.
87. Grizzle WE, Adam BL, Bigbee WL, Conrads TP, Carroll C, Feng Z, et al. Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer. Dis Markers 2003;19:185-95.
88. Malik G, Ward MD, Gupta SK, Trosset MW, Grizzle WE, Adam BL, et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res 2005;11:1073-85.
89. Poon TC, Chow SM, Ma BBY. Serum proteomic pattern for predicting recurrence of undifferentiated naopharyngeal carcinoma after radiotherapy - a potetial surrogate marker. Clin Proteomics 2004;1:365-76.
90. Goncalves A, Esterni B, Bertucci F, Sauvan R, Chabannon C, Cubizolles M, et al. Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene 2006;25:981-9.
91. Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 2003;3:1486-94.
92. Bradbury LE, LeBlanc JF, McCarthy DB. ProteinChip array-based amyloid beta assays. Methods Mol Biol 2004;264:245-57.
93. Austen BM, Frears ER, Davies H. The use of seldi protein-chip arrays to monitor production of Alzheimer's betaamyloid in transfected cells. J Pept Sci 2000;6:459-69.
94. Lewczuk P, Esselmann H, Groemer TW, Bibl M, Maler JM, Steinacker P, et al. Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. Biol Psychiatry 2004;55:524-30.
95. Lewczuk P, Esselmann H, Meyer M, Wollscheid V, Neumann M, Otto M, et al. The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide. Rapid Commun Mass Spectrom 2003;17:1291-6.
96. Uchida T, Fukawa A, Uchida M, Fujita K, Saito K. Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid. J Proteome Res 2002;1:495-9.
97. Allard L, Lescuyer P, Burgess J, Leung KY, Ward M, Walter N, et al. ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke. Proteomics 2004;4:2242-51.
98. Suzuyama K, Shiraishi T, Oishi T, Ueda S, Okamoto H, Furuta M, et al. Combined proteomic approach with SELDI-TOF-MS and peptide mass fingerprinting identified the rapid increase of monomeric transthyretin in rat cerebro-spinal fluid after transient focal cerebral ischemia. Brain Res Mol Brain Res 2004;129:44-53.
99. Kiehntopf M, Osterloh D, Driesch D, Eggeling Fv, Melle C, Brunkhorst FM, et al. Application of the SELDI ProteinChip System for the identification of distinct protein patterns in plasma from patients with non-infectious SIRS, infectious-induced SIRS and controls. In: NIH-Symposium on the Functional Genomics of Critical Illness and Injury; 2003;Bethesda, November 17-18; 2003.
100. Kiehntopf M, Osterloh D, von Eggeling F, Brunkhorst FM, Reinhart K, Deufel T, et al. SELDI-based protein patterns in the diagnosis of Sepsis/SIRS. In: Congress of Clinical Chemistry and Laboratory Medicine 2nd Annual Conference of the German United Society for Clinical Chemistry and Laboratory Medicine (DGKL) together with the Austrian Society for Laboratory Medicine and Clinical Chemistry (ÖGLMKC); 2005 October 6-8, 2005; Jena, Germany; 2005. p. V22.
101. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004;4:367-78.
102. Villar-Garea A, Griese M, Imhof A. Biomarker discovery from body fluids using mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2006;849:105-14.
103. Koomen JM, Shih LN, Coombes KR, Li D, Xiao LC, Fidler IJ, et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 2005;11:1110-8.
104. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004;96:353-6.
105. Rogers MA, Clarke P, Noble J, Munro NP, Paul A, Selby PJ, et al. Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res 2003;63:6971-83.
106. Hilario M, Kalousis A, Pellegrini C, Muller M. Processing and classification of protein mass spectra. Mass Spectrom Rev 2006;25:409-49.
107. Vorderwülbecke S, Cleverley S, Weinberger SR, Wiesner A. Protein quantification by the SELDI-TOF-MS-based ProteinChip® System. Nat Methods 2005;2:393-5.
108. Malyarenko DI, Cooke WE, Adam BL, Malik G, Chen H, Tracy ER, et al. Enhancement of Sensitivity and Resolution of Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometric Records for Serum Peptides Using Time-Series Analysis Techniques. Clin Chem 2004;51:65-74.
109. Shiwa M, Nishimura Y, Wakatabe R, Fukawa A, Arikuni H, Ota H, et al. Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochem Biophys Res Commun 2003;309:18-25.
110. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003;422:198-207.
111. Mann M, Hendrickson RC, Pandey A. Analysis of proteins and proteomes by mass spectrometry. Annu Rev Biochem 2001;70:437-73.
112. Gillette MA, Mani DR, Carr SA. Place of pattern in proteomic biomarker discovery. J Proteome Res 2005;4:1143-54.
113. Cohen SL, Chait BT. Influence of matrix solution conditions on the MALDI-MS analysis of peptides and proteins. Anal Chem 1996;68:31-7.
114. West-Norager M, Kelstrup CD, Schou C, Hogdall EV, Hogdall CK, Heegaard NH. Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics. J Chromatogr B Analyt Technol Biomed Life Sci 2007;847:30-7.
115. Dreisewerd K. The desorption process in MALDI. Chem Rev 2003;103:395-426.
116. Kratzer R, Eckerskorn C, Karas M, Lottspeich F. Suppression effects in enzymatic peptide ladder sequencing using ultraviolet-matrix assisted laser desorption/ionization-mass spectormetry. Electrophoresis 1998;19:1910-9.
117. Baumgart S, Lindner Y, Kuhne R, Oberemm A, Wenschuh H, Krause E. The contributions of specific amino acid side chains to signal intensities of peptides in matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom 2004;18:863-8.
118. Ang IL, Poon TC, Lai PB, Chan AT, Ngai SM, Hui AY, et al. Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach. J Proteome Res 2006;5:2691-700.
119. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845-67.
120. Schulte I, Tammen H, Selle H, Schulz-Knappe P. Peptides in body fluids and tissues as markers of disease. Expert Rev Mol Diagn 2005;5:145-57.
121. Semmes OJ, Cazares LH, Ward MD, Qi L, Moody M, Maloney E, et al. Discrete serum protein signatures discriminate between human retrovirus-associated hematologic and neurologic disease. Leukemia 2005;19:1229-38.
122. Ye B, Cramer DW, Skates SJ, Gygi SP, Pratomo V, Fu L, et al. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 2003;9:2904-11.
123. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006;116:271-84.
124. Liotta LA, Petricoin EF. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 2006;116:26-30.
125. Marshall J, Kupchak P, Zhu W, Yantha J, Vrees T, Furesz S, et al. Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J Proteome Res 2003;2:361-72.
126. Banks RE, Stanley AJ, Cairns DA, Barrett JH, Clarke P, Thompson D, et al. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem 2005;51:1637-49.
127. Timms JF, Arslan-Low E, Gentry-Maharaj A, Luo Z, T'Jampens D, Podust VN, et al. Preanalytic Influence of Sample Handling on SELDI-TOF Serum Protein Profiles. Clin Chem 2007.
128. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, et al. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002;48:1835-43.
129. Aivado M, Spentzos D, Alterovitz G, Otu HH, Grall F, Giagounidis AA, et al. Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) with reversed-phase protein arrays for protein profiling. Clin Chem Lab Med 2005;43:133-40.
130. Cordingley HC, Roberts SL, Tooke P, Armitage JR, Lane PW, Wu W, et al. Multifactorial screening design and analysis of SELDI-TOF ProteinChip array optimization experiments. Biotechniques 2003;34:364-5, 368-73.
131. Jock CA, Paulauskis JD, Baker D, Olle E, Bleavins MR, Johnson KJ, et al. Influence of matrix application timing on spectral reproducibility and quality in SELDI-TOF-MS. Biotechniques 2004;37:30-2, 34.